Jacques Azzi

机构：Icahn School of Medicine at Mount Sinai · ORCID：0000-0002-9862-8669

发表论文 48 篇 · 总被引 699 次 · h-index 11

代表论文

• Checkpoint inhibitor‐based salvage regimens prior to autologous stem cell transplant improve event‐free survival in relapsed/refractory classic Hodgkin lymphoma (2023 · American Journal of Hematology · 被引 36)
• Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation (2023 · Blood · 被引 13)
• A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT (2026 · Blood · 被引 9)
• Acute Graft‐versus‐Host Disease (2023 · 被引 5)
• Cryopreservation of Allogeneic Hematopoietic Cell Products During COVID-19 Pandemic: Graft Characterization and Engraftment Outcomes (2023 · Transplantation Proceedings · 被引 5)
• POS0656 TOLERABILITY AND EFFICACY OF BMS-986353 (CC-97540), A CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY MANUFACTURED USING A NEXT-GENERATION PROCESS FOR SYSTEMIC SCLEROSIS: UPDATED DATA FROM THE PHASE 1 BREAKFREE-1 STUDY (2025 · Annals of the Rheumatic Diseases · 被引 4)